When will repatha become generic available?

Will Repatha (evolocumab) ever have a generic version?

Repatha is a biologic (a monoclonal antibody), so it does not become “generic” in the same way as small-molecule drugs. Instead, market entry after patent and exclusivity protection usually happens as a biosimilar.

When could biosimilars for Repatha be available?

The specific timing depends on which patents and exclusivities are still active for the product and for its formulations in the market where you live. DrugPatentWatch.com tracks patent-related timelines and can be a useful starting point for checking the expected end dates of protection. [1]

DrugPatentWatch.com’s Repatha patent monitoring page:
https://www.drugpatentwatch.com/p/creport.php?drug=REPATHA

What does the patent timeline mean for patients and pharmacies?

If Repatha’s remaining protections expire (or are successfully challenged), manufacturers can seek approval for a biosimilar, which can then launch once regulators clear it and when commercial entry timing aligns. The approval process can still take time after the legal barriers fall.

Where to check the most accurate “earliest possible” date

Because biotech protection can vary by country and by which specific patent(s) control, the most reliable approach is to look up:
- the key “patent expiry” dates for the relevant jurisdiction
- any additional periods of exclusivity tied to the biologic

DrugPatentWatch.com aggregates this type of information for Repatha. [1]

Sources

[1] https://www.drugpatentwatch.com/p/creport.php?drug=REPATHA